Prudential Financial Inc. grew its stake in LivaNova PLC (NASDAQ:LIVN - Free Report) by 10.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 155,227 shares of the company's stock after purchasing an additional 14,950 shares during the quarter. Prudential Financial Inc. owned approximately 0.29% of LivaNova worth $7,189,000 as of its most recent SEC filing.
Other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in LivaNova by 12.7% in the 4th quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock valued at $108,823,000 after acquiring an additional 265,291 shares during the period. Point72 Asset Management L.P. increased its stake in shares of LivaNova by 62.7% during the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company's stock worth $109,914,000 after purchasing an additional 806,374 shares during the period. Geode Capital Management LLC lifted its holdings in LivaNova by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company's stock worth $70,676,000 after purchasing an additional 8,331 shares during the last quarter. Emerald Advisers LLC boosted its stake in LivaNova by 8.2% in the 4th quarter. Emerald Advisers LLC now owns 752,540 shares of the company's stock valued at $34,850,000 after purchasing an additional 57,035 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in LivaNova by 17.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 621,959 shares of the company's stock valued at $32,678,000 after buying an additional 93,311 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
LivaNova Price Performance
Shares of LivaNova stock traded down $1.53 on Friday, reaching $35.95. 1,262,294 shares of the stock were exchanged, compared to its average volume of 616,086. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The firm has a market cap of $1.95 billion, a PE ratio of 85.60 and a beta of 0.90. The firm's 50 day moving average is $43.47 and its 200-day moving average is $48.12. LivaNova PLC has a one year low of $35.28 and a one year high of $64.48.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on LIVN shares. Needham & Company LLC reissued a "buy" rating and set a $64.00 target price on shares of LivaNova in a report on Monday, March 17th. Mizuho dropped their price objective on shares of LivaNova from $70.00 to $60.00 and set an "outperform" rating for the company in a research note on Wednesday, February 26th. The Goldman Sachs Group decreased their target price on shares of LivaNova from $64.00 to $55.00 and set a "buy" rating on the stock in a research report on Monday, March 3rd. Stifel Nicolaus dropped their price target on shares of LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. Finally, Barclays cut their price target on LivaNova from $58.00 to $56.00 and set an "equal weight" rating for the company in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $61.17.
Read Our Latest Report on LIVN
About LivaNova
(
Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Featured Stories
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
